INCB-186748
- Generic Name
- INCB-186748
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1
Recruiting
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 308
- Registration Number
- NCT06818812
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath